ES2594900T3 - Método para tratar cicatrices y trastornos mediados por beta-catenina - Google Patents

Método para tratar cicatrices y trastornos mediados por beta-catenina Download PDF

Info

Publication number
ES2594900T3
ES2594900T3 ES10836897.8T ES10836897T ES2594900T3 ES 2594900 T3 ES2594900 T3 ES 2594900T3 ES 10836897 T ES10836897 T ES 10836897T ES 2594900 T3 ES2594900 T3 ES 2594900T3
Authority
ES
Spain
Prior art keywords
nefopam
compound
scars
scar
catenin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10836897.8T
Other languages
English (en)
Spanish (es)
Inventor
Benjamin A. Alman
Raymond Poon
Helen Hong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children
Original Assignee
Hospital for Sick Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44166687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2594900(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospital for Sick Children filed Critical Hospital for Sick Children
Application granted granted Critical
Publication of ES2594900T3 publication Critical patent/ES2594900T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
ES10836897.8T 2009-12-15 2010-12-15 Método para tratar cicatrices y trastornos mediados por beta-catenina Active ES2594900T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28663309P 2009-12-15 2009-12-15
US286633P 2009-12-15
PCT/CA2010/002014 WO2011072394A1 (en) 2009-12-15 2010-12-15 METHOD OF TREATING SCARS AND ß-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS

Publications (1)

Publication Number Publication Date
ES2594900T3 true ES2594900T3 (es) 2016-12-23

Family

ID=44166687

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10836897.8T Active ES2594900T3 (es) 2009-12-15 2010-12-15 Método para tratar cicatrices y trastornos mediados por beta-catenina

Country Status (10)

Country Link
US (4) US8957107B2 (enExample)
EP (1) EP2512468B1 (enExample)
JP (1) JP5792185B2 (enExample)
KR (1) KR101753439B1 (enExample)
CN (2) CN102781442B (enExample)
BR (1) BR112012014471A2 (enExample)
CA (1) CA2782472C (enExample)
DK (1) DK2512468T3 (enExample)
ES (1) ES2594900T3 (enExample)
WO (1) WO2011072394A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781442B (zh) * 2009-12-15 2016-02-17 儿童医院 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11266637B2 (en) * 2018-06-01 2022-03-08 Iterion Therapeutics, Inc. Formulations of tegavivint and related compounds
CN110638780A (zh) * 2019-09-11 2020-01-03 华益药业科技(安徽)有限公司 一种盐酸奈福泮片及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0213869D0 (en) * 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
PT1572672E (pt) 2002-12-20 2008-10-02 Sosei R & D Ltd Benzoxazocinas e sua utilização como inibidores de reabsorção de monoamina
US20060019940A1 (en) 2002-12-20 2006-01-26 Baxter Andrew D Novel benzoxazocines and their therapeutic use
GB0330049D0 (en) 2003-12-24 2004-02-04 Arakis Ltd The treatment of neuropathic pain conditions
WO2005103019A1 (en) 2004-04-21 2005-11-03 Sosei R&D Ltd. Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors
GB2413322A (en) 2004-04-21 2005-10-26 Arakis Ltd Nefopam analogues
CN1569004A (zh) * 2004-05-13 2005-01-26 南昌弘益科技有限公司 盐酸奈福泮滴丸及其制备方法
FR2880275B1 (fr) 2005-01-06 2007-04-13 Biocodex Utilisation de composes pharmacologiques pour la prevention ou le traitement de la tolerance aigue aux morphiniques
GB0506835D0 (en) 2005-04-04 2005-05-11 Arakis Ltd Therapeutic use of nefopam
GB0515703D0 (en) 2005-07-29 2005-09-07 Arakis Ltd Therapeutic use of nefopam
CN101002756A (zh) 2007-01-19 2007-07-25 陶燃 盐酸奈福泮的透皮贴片制剂
GB0721013D0 (en) 2007-10-25 2007-12-05 Sosei R & D Ltd New Salts
MX2010013931A (es) 2008-06-16 2011-06-01 Academia Sinica Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos.
GB2461874B (en) 2008-07-14 2012-11-21 Caltec Ltd Separation system and method
FR2940911B1 (fr) * 2009-01-13 2012-09-21 Philippe Perovitch Formulation pour l'administration par voie trans-muqueuse buccale de molecules antalgiques et/ou anti-spasmodiques
CN102781442B (zh) * 2009-12-15 2016-02-17 儿童医院 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法

Also Published As

Publication number Publication date
WO2011072394A1 (en) 2011-06-23
EP2512468B1 (en) 2016-08-24
US8957107B2 (en) 2015-02-17
HK1174565A1 (zh) 2013-06-14
CN105687185A (zh) 2016-06-22
US20150105363A1 (en) 2015-04-16
US9566263B2 (en) 2017-02-14
CN102781442A (zh) 2012-11-14
HK1224224A1 (zh) 2017-08-18
DK2512468T3 (en) 2016-11-14
CN105687185B (zh) 2019-07-09
CA2782472A1 (en) 2011-06-23
JP5792185B2 (ja) 2015-10-07
KR101753439B1 (ko) 2017-07-19
CA2782472C (en) 2019-04-16
US20170172980A1 (en) 2017-06-22
US10722493B2 (en) 2020-07-28
KR20120110117A (ko) 2012-10-09
BR112012014471A2 (pt) 2017-06-06
US20170281594A1 (en) 2017-10-05
EP2512468A4 (en) 2013-08-07
JP2013513625A (ja) 2013-04-22
CN102781442B (zh) 2016-02-17
EP2512468A1 (en) 2012-10-24
US20120294928A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
ES2473577T3 (es) Composición antioxidante que comprende galactomanano y N-acetil-ciste�na
US10808250B2 (en) Fidgetin-like 2 as a target to enhance wound healing
US10722493B2 (en) Methods for treating fibroproliferative disorders in a mammal
US20180344680A1 (en) Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
Shen et al. Liensinine prevents ischemic injury following myocardial infarction via inhibition of Wnt/β‑catenin signaling activation
US20230302191A1 (en) Compositions and methods for sustained oxygen release to ischemic tissues
AU2017242155B2 (en) Stable pharmaceutical compositions for topical administration and uses thereof
HK1224224B (en) Method of treating aggressive fibromatoses and betacatenin-mediated disorders using nefopam compounds
ES3012548T3 (en) Thiadiazolidinones for their use in the treatment of limb-girdle muscular dystrophy
KR102561856B1 (ko) 염증성 질환의 예방, 개선 또는 치료용 조성물
CA3246700A1 (en) WOUND TREATMENT COMPOSITION
HK1174565B (en) Method of treating scars and ss-catenin-mediated disorders using nefopam compounds
IT202200000347A1 (it) Composti utili nella prevenzione e/o trattamento di patologie e malattie associate a cellule senescenti.
KR20220069909A (ko) 베라파밀을 포함하는 창상 치유용 조성물
Guo et al. Swimming Alleviates Myocardial Fibrosis of Type Ii Diabetic Rats Through Activating Irisin Via the Mir-34a-Mediated Sirt1/Pgc-1α/Fndc5 Signal Pathway
BR112015030569B1 (pt) Uso de compostos anti-fibrogênicos